The life science industry is all hands on deck in the race to develop vaccines, therapies and diagnostics in the fight against coronavirus. But while some prosper, many in the sector are forced to halt clinical trials and mothball labs
Receive the Funding Newswire [full access requires a subscription] each Tuesday, our Policy Bulletin each Thursday, and the fortnightly R&D Express, tracking reforms and investments in central and eastern Europe.
A unique international forum for public research organisations and companies to connect their external engagement with strategic interests around their R&D system.